Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL6377759 | 0.94 | CYP2A6 (0.60) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| Methane SCHEMBL2790892 | 0.86 | CYP2A6 (0.56) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL91191 | 0.83 | CYP2A6 (0.62) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL16398945 | 0.83 | CYP2A6 (0.67) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL3789614 | 0.80 | CYP2A6 (0.58) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL2248829 | 0.80 | CYP2A6 (1.00) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL13338100 | 0.80 | CYP2A6 (0.58) | CYP2A6CA1CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1273504 | 0.79 | CYP2A6 (0.56) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL22917119 | 0.79 | CYP2A6 (0.56) | CYP2A6CA1CA2ALDH1A1CHRNA7 | |
| SCHEMBL368354 | 0.79 | CYP2A6 (0.56) | CYP2A6CA1CA2ALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107255628-A | A kind of formaldehyde testing reagent | 湖南师范大学 | 2017-10-17 | — | — | CN | claimed |
| CN-107159301-A | A kind of base supported mimetic enzyme catalyst of zeolite and its preparation method and application | 复旦大学 | 2017-09-15 | — | — | CN | claimed |
| CN-103073522-B | Synthesis method of 2,2' -biazoyl-di (3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt | 江西师范大学 | 2017-06-06 | — | — | CN | claimed |
| WO-2006056595-A1 | KEROSENE COMPOSITIONS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2006-06-01 | — | — | WO | claimed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2001053432-A1 | SULFUR REMOVAL PROCESS | BP CORPORATION NORTH AMERICA INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-1029024-A1 | MULTIPLE STAGE SULFUR REMOVAL PROCESS | BP Corporation North America Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-1029025-A2 | SULFUR REMOVAL PROCESS | BP Amoco Corporation (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6059962-A | FOR HYDROCARBON FEEDSTOCK; ALKYLATION, DISTILLATION | BP AMOCO CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| WO-2000014182-A2 | SULFUR REMOVAL PROCESS | BP AMOCO CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000014181-A1 | MULTIPLE STAGE SULFUR REMOVAL PROCESS | BP AMOCO CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
| US-6024865-A | Sulfur removal process | BP AMOCO CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0636622-A1 | Isoxazole derivatives and their use as herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | CYP2A6 873/4885CA1 4812/4885CA2 4351/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | CYP2A6 2270/4885CA1 1664/4885CA2 2888/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2A6 1619/4885CA1 4151/4885CA2 2999/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | CYP2A6 4263/4885CA1 4224/4885CA2 3320/4885 |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, DPM1 | CYP2A6 3878/4885CA1 4166/4885CA2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.